EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epigenetic Plasticity in Lung Cancer Therapy Resistance: Mechanisms, Biomarkers, and Rational Combination Strategies

Buse Eglenen Polat, Renuka Meenu Ramchandran, Jihua Yang, Meng Wang, Haiying Cheng

Genes · 16.11.2026 · 17 (11) · 1442

DOI: 10.3390/genes17111442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, online erschienen am 16.11.2026. Verfasst von Buse Eglenen Polat und 4 weiteren Autor:innen. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer resistance is commonly attributed to acquired genetic alterations, including on-target mutations, activation of bypass pathways, tumor-suppressor loss, and histologic or lineage transformation. However, genetic evolution alone cannot fully account for the rapid, reversible, and heterogeneous adaptations that emerge during treatment. Epigenetic plasticity, mediated through DNA methylation, histone modifications, chromatin-remodeling complexes, and transcriptional state transitions, enables tumor cells to enter drug-tolerant states, alter lineage identity, evade immune surveillance, and persist under therapeutic pressure, creating conditions in which more stable forms of resistance can develop. This review examines how epigenetic programs interact with oncogenic drivers and tumor-suppressor loss to shape therapy resistance across lung cancer. We discuss chromatin-mediated resistance to targeted therapies, cytotoxic chemotherapy, and immune checkpoint blockade, with particular attention to drug-tolerant persister states, epithelial–mesenchymal and neuroendocrine transitions, impaired antigen presentation, and remodeling of the tumor microenvironment. We critically assess the evidence for DNA methyltransferase and histone deacetylase inhibitors, together with emerging strategies targeting EZH2/EZH1, LSD1, BET proteins, PRMT5/MAT2A, and vulnerabilities associated with SWI/SNF dysfunction. Clinical translation has been limited by modest single-agent activity, treatment-related toxicity, incomplete pharmacodynamic assessment, and inadequate biomarker-based patient selection. Future progress will depend on matching epigenetic interventions to defined biological states, confirming intratumoral target engagement, and integrating longitudinal multiomic profiling to guide patient selection, treatment sequencing, and early interception of emerging resistance.

Zitieren

APA

Polat, B. E., Ramchandran, R. M., Yang, J., Wang, M., & Cheng, H. (2026). Epigenetic Plasticity in Lung Cancer Therapy Resistance: Mechanisms, Biomarkers, and Rational Combination Strategies. Genes, 17(11), 1442. https://doi.org/10.3390/genes17111442

Vancouver

Polat BE, Ramchandran RM, Yang J, Wang M, Cheng H. Epigenetic Plasticity in Lung Cancer Therapy Resistance: Mechanisms, Biomarkers, and Rational Combination Strategies. Genes. 2026;17(11):1442. doi:10.3390/genes17111442

BibTeX
@article{Polat2026,
  author = {Polat, Buse Eglenen and Ramchandran, Renuka Meenu and Yang, Jihua and Wang, Meng and Cheng, Haiying},
  title = {Epigenetic Plasticity in Lung Cancer Therapy Resistance: Mechanisms, Biomarkers, and Rational Combination Strategies},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {11},
  pages = {1442},
  doi = {10.3390/genes17111442}
}
Kostenlos starten →